> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Arcutis’ Zoryve Topical Foam for Dermatitis
- URL: https://www.fdaweb.com/fda-oks-arcutis-zoryve-topical-foam-for-dermatitis/
- Published: 2024-01-02T12:00:00.000Z
- Updated: 2026-09-14T14:19:24.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5156011

FDA has approved an Arcutis Biotherapeutics’ NDA for Zoryve (roflumilast) topical foam, 0.3%, to treat seborrheic dermatitis in individuals age nine and older. A company [statement](https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-topical-foam-0-3-for-the-treatment-of-seborrheic-dermatitis-in-individuals-aged-9-years-and-older/?ref=fdaweb.com) says Zoryve foam provides rapid disease clearance and a significant reduction in itch. The company says it is a once-daily steroid-free foam and the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.

Roflumilast is described as a highly potent and selective phosphodiesterase-4 inhibitor.